摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-[[4-[4-(aminoiminomethyl)benzoyl]-1-piperazinyl]carbonyl]-5-[[4-(aminoiminomethyl)-1-piperazinyl]methyl]-benzoic acid | 1379573-94-0

中文名称
——
中文别名
——
英文名称
3-[[4-[4-(aminoiminomethyl)benzoyl]-1-piperazinyl]carbonyl]-5-[[4-(aminoiminomethyl)-1-piperazinyl]methyl]-benzoic acid
英文别名
3-[4-(4-Carbamimidoylbenzoyl)piperazine-1-carbonyl]-5-[(4-carbamimidoylpiperazin-1-yl)methyl]benzoic acid
3-[[4-[4-(aminoiminomethyl)benzoyl]-1-piperazinyl]carbonyl]-5-[[4-(aminoiminomethyl)-1-piperazinyl]methyl]-benzoic acid化学式
CAS
1379573-94-0
化学式
C26H32N8O4
mdl
——
分子量
520.591
InChiKey
JSSJJDPNCJIRJA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -2.9
  • 重原子数:
    38
  • 可旋转键数:
    7
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.35
  • 拓扑面积:
    184
  • 氢给体数:
    5
  • 氢受体数:
    7

文献信息

  • Novel Suicidal LSD1 Inhibitors Targeting SOX2-Expressing Cancer Cells
    申请人:THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BE HALF OF THE UNIVERSITY OF N
    公开号:US20160120862A1
    公开(公告)日:2016-05-05
    Disclosed are inhibitors of lysine-specific demethylase I (LSD1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating cancers characterized by the presence of Sox2 using the compounds and compositions Also disclosed are methods of treating cancers characterized by the presence of Sox2 using inhibitors of LSD1 and/or histone deacetylation I (HDAC1). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    本发明涉及一种赖酸特异性去甲基化酶I(LSD1)的抑制剂,合成该化合物的方法,包含该化合物的制药组合物以及使用该化合物和组合物治疗存在Sox2的癌症的方法。本发明还涉及使用LSD1和/或组蛋白去乙酰化酶I(HDAC1)的抑制剂治疗存在Sox2的癌症的方法。本摘要旨在作为搜索特定领域的扫描工具,不限制本发明。
  • IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY
    申请人:Motz Gregory
    公开号:US20190000880A1
    公开(公告)日:2019-01-03
    Provided are the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen.
  • US9918983B2
    申请人:——
    公开号:US9918983B2
    公开(公告)日:2018-03-20
  • [EN] NOVEL SUICIDAL LSD1 INHIBITORS TARGETING SOX2-EXPRESSING CANCER CELLS<br/>[FR] NOUVEAUX INHIBITEURS SUICIDES DE LA LSD1 CIBLANT LES CELLULES CANCÉREUSES EXPRIMANT LE SOX2
    申请人:UNIV NEVADA
    公开号:WO2014194280A2
    公开(公告)日:2014-12-04
    Disclosed are inhibitors of lysine-specific demethylase I (LSD1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating cancers characterized by the presence of Sox2 using the compounds and compositions Also disclosed are methods of treating cancers characterized by the presence of Sox2 using inhibitors of LSD 1 and/or histone deacetylation I (HDAC1). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
查看更多